Transcriptomics

Structure of the eye
#Mogrify #Preclinical development #Retinal diseases #Transcriptomics

MOGRIFY-derived transcription factors preserve functional vision

Mogrify will present preclinical proof-of-concept data at FLORetina-ICOOR 2026 in support its first-in-class therapy designed to protect and regenerate the retina in patients with retinal disorders.  The company’s lead programme uses transcription factor-mediated direct reprogramming to convert müller glial cells into functional photoreceptors within the retina.  … Read More

#News

#Flagship Pioneering #Foundational model #Start-ups #Transcriptomics

New company Etcelera unites three drug discovery platforms

Flagship Pioneering has announced the formation of Etcelera, a company created by the merger of the platforms of Cellarity, Etiome and Empress Therapeutics.  The new company aims to pioneer causal intelligence in human biology: the ability to determine what truly drives disease and predict how a medicine… Read More

#Business & Investment #News #Start-up Zone

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Available on-demand: How DRUG-seq enables data-rich compound screening

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Don’t forget to watch: Building the data layer for AI drug discovery

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Watch now: Building data with phenotypic and transcriptomic workflows

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Webinar: Learn how to build rich datasets for drug discovery

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Webinar: Building the data layer for AI drug discovery

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Building the data layer for Al drug discovery: Cell painting and DRUG-seq in large-scale compound screens

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at Alithea Genomics,… Read More

Webinar date:
Supported by Alithea Genomics and Revvity
#Webinars

#AI #Drug discovery #Genomics #Multiomics #Transcriptomics

Advances in genomics for drug discovery 

DDW Editor Reece Armstrong speaks to Michelle Carlson about overall advances in genomics and the integration of emerging technologies to create more drug discovery and development opportunities.  RA: How is long-read sequencing enabling greater clinical research… Read More

#Exclusive Content

#Artificial intelligence (AI) #Collaboration #PRISM BioLab #Talus Biosciences #Transcriptomics

Talus Bio and PRISM BioLab collaborate on TF and PPI targets

Talus Bioscience and PRISM BioLab have agreed to join forces with the aim of accelerating the discovery and development of novel small-molecule modulators of transcription factor (TF) and protein-protein interaction (PPI) targets.   The collaboration combines Talus Bio’s regulome profiling and AI-guided drug discovery platform with PRISM’s chemistry… Read More

#Business & Investment #News

#RNA #SPT Labtech #Transcriptomics

Alithea Genomics partners with SPT Labtech on transcriptomics 

Biotechnology company Alithea Genomics has announced a collaboration with manufacturer SPT Labtech to provide an automated solution for single-cell transcriptomics.   The collaboration integrates Alithea Genomics’ ultra-sensitive single-cell RNA-seq technology, MERCURIUS FLASH-seq, with SPT Labtech’s firefly liquid handling platform, which the companies say will create a scalable and reproducible workflow… Read More

#Business & Investment #News

Sickle cells
#Artificial intelligence (AI) #Cellarity #Phase I trial #Sickle cell disorder (SCD) #Transcriptomics

Globin-Switching drug reduces sickle cell disease symptoms

Biotech Cellarity has dosed its first patient in a Phase I clinical trial of CLY-124, a first-in-class Globin-Switching oral medicine designed to treat sickle cell disease (SCD).   “Initiation of our first-in-human clinical study for CLY-124 represents the delivery of our first clinical asset from our platform with… Read More

#News

Trophy
#AI #Cancer research #Drug discovery #Nebius #Protein targets #Transcriptomics

Nebius accelerates next generation of AI discovery innovation

DDW’s Megan Thomas attended Nebius’ inaugural AI Discovery Awards in Amsterdam, where top prizes of $100,000 in GPU credits were awarded to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics. The winners were selected from 257 global applications by a panel of 19… Read More

#News

Grandfather and grandson
#Age-related diseases (ARDs) #Ageing #Rejuvenation therapies #Shift Bioscience #Transcriptomics

Novel single-gene target reverses cellular ageing

Biotechnology company Shift Bioscience has published new research identifying a novel, single-gene target for cellular rejuvenation.   Capable of reversing cellular ageing across multiple cell types, without inducing dangerous pluripotency pathways seen in other approaches, the company says SB000 is well positioned as a target for safer, next-generation… Read More

#Editor's Choice #News

#Oncology #Peptides #Transcriptomics #University of Bath

Promising drug candidates for previously ‘undruggable’ target

Reportedly for the first time, researchers from the University of Bath have identified  promising  drug candidates that bind irreversibly with a notoriously ‘undruggable’ cancer protein target, permanently blocking it. Transcription factors are proteins that act as ‘master switches’ of gene activity and play a key role in cancer… Read More

#Cancer Research #News #Trending News

Ageing hands
#Ageing #Healthspan #Junevity #Seed funding #siRNA #Transcriptomics

Biotech raises $10m to address ageing at a cellular level

Junevity, a biotechnology company hoping to extend lifespan and healthspan by resetting cell damage from age-related diseases, has announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital.  The Junevity RESET platform is based on exclusively licensed research by co-founder Dr Janine Sengstack at… Read More

#Business & Investment #News